Research paperCharge transfer in trans-combretastatins

Add time:08/14/2019    Source:sciencedirect.com

The non-toxic trans isomer of combretastatin-A4 can be photoisomerised in physiological conditions to cis-CA4, a potential anticancer drug. Absorption at wavelengths with high tissue penetration can be achieved by functionalization with substituents influencing the degree of charge-transfer (CT) of the S1 state, in which the isomerisation occurs. We present a TDDFT study of the excited state properties of a series of substituted combretastatins with various degrees of CT character. Increasing the CT character determines a redshift of absorption and an intensity enhancement, but it disfavours the isomerisation. An appropriate choice of substituents is therefore required to achieve optimal isomerisation conditions.

We also recommend Trading Suppliers and Manufacturers of combretastatin B-3 (cas 116518-76-4). Pls Click Website Link as below: cas 116518-76-4 suppliers

Prev:Stimulation of ganglionic muscarinic M1 receptors by a series of tertiary arecaidine and isoarecaidine esters in the pithed rat
Next:Research paperPhotoresponsive azo-combretastatin A-4 analogues)